With only one holder of record and a prior delisting notice, the company has effectively completed a going-private transaction. Monitor for any subsequent OTC trading updates or a final merger filing; the stock is now essentially illiquid for public investors.
Price Chart
Executive Summary
Theravance Biopharma filed a Form 15 to terminate its SEC registration and suspend reporting obligations, effective October 5, 2026. The filing follows a prior exchange delisting notice (25-NSE) and confirms the company has only one holder of record, indicating a completed going-private transaction or buyout. Existing shareholders lose SEC transparency and likely face OTC trading with reduced liquidity.
Key Facts
- Filed Form 15 on October 5, 2026 to terminate registration under Section 12(g) and suspend reporting under Sections 13 and 15(d).
- Approximate number of holders of record as of certification date: one (1).
- Exchange delisting notice (25-NSE) was filed 12 days prior, on September 23, 2026.
- Securities covered: Ordinary Shares, par value $0.00001 per share.
- Registrant's principal executive offices: South San Francisco, California.
Financial Impact
No financial figures provided; the deregistration eliminates SEC reporting obligations, reducing transparency for remaining shareholders.
Risk Factors
- Complete loss of SEC reporting and transparency for shareholders.
- Likely transition to OTC markets with significantly reduced liquidity and price discovery.
- No further public financial disclosures required, increasing information asymmetry.
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 15-12G Filing (Primary) | 0001104659-26-113695 |
| Document: 0001104659-26-113695-index-headers.html | 0001104659-26-113695 |
| Document: 0001104659-26-113695-index.html | 0001104659-26-113695 |
| Document: 0001104659-26-113695.txt | 0001104659-26-113695 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 5, 2026 21d ago | 15-12G | — | awaiting T+20 | — | — |
Sep 25, 2026 4w ago | SC 13D/A | $17.04 | awaiting T+20 | — | — |
Sep 23, 2026 4w ago | 25-NSE | $17.05 | awaiting T+20 | — | — |
Aug 25, 2026 8w ago | DEFA14A | $17.03 $17.03 | · 0.00% | ▼ −0.23% | — |
Aug 21, 2026 9w ago | DEFM14A | $17.01 $17.05 | ▲ +0.24% | ▲ +0.76% | — |
Aug 11, 2026 11w ago | PREM14A | $16.91 $17.06 | ▲ +0.89% | ▲ +1.95% | — |
Aug 10, 2026 11w ago | 8-K | $16.91 $17.06 | ▲ +0.89% | ▲ +1.80% | — |
Jun 29, 2026 17w ago | 8-K | $17.06 $16.86 | ▼ −1.17% | ▼ −0.89% | — |
Jun 23, 2026 17w ago | 8-K | $17.27 $16.81 | ▼ −2.66% | ▼ −4.60% | — |
May 7, 2026 24w ago | 8-K | $17.02 $15.92 | ▼ −6.46% | ▼ −9.60% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers